The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase Ib study of selinexor and eribulin combination in advanced solid tumors and triple-negative breast cancer.
 
Blessie Elizabeth Nelson
No Relationships to Disclose
 
Sadia Saleem
No Relationships to Disclose
 
Senthil Damodaran
Research Funding - EMD Serono (Inst); Guardant Health (Inst); Novartis (Inst); Sermonix Pharmaceuticals (Inst); Taiho Pharmaceutical (Inst)
 
Neeta Somaiah
Stock and Other Ownership Interests - JNJ (I); Pfizer (I)
Consulting or Advisory Role - AADi; Bayer; Blueprint Medicines; Boehringer Ingelheim; Deciphera; Epizyme
Research Funding - Ascentage Pharma; AstraZeneca/MedImmune (Inst); Daiichi Sankyo/Lilly; Deciphera; GlaxoSmithKline; Karyopharm Therapeutics
 
Sarina Anne Piha-Paul
Consulting or Advisory Role - CRC Oncology
Research Funding - Abbvie (Inst); ABM (Inst); Acepodia (Inst); Alkermes (Inst); Aminex (Inst); Amphivena Therapetics, Inc. (Inst); Biomarin (Inst); Boehringer Ingelheim (Inst); Bristol Myers Squib (Inst); Cerulean Pharma (Inst); Chugai Pharma (Inst); Curis (Inst); Cyclacel (Inst); Daichi Sanko (Inst); ENB Therapeutics (Inst); F-Star Beta Limited (Inst); F-Star Therapeutics, Ltd. (Inst); Five Prime Therapeutics (Inst); Gene Quantum (Inst); Genmab (Inst); GlaxoSmithKline (Inst); Helix BioPharma (Inst); HiberCell (Inst); Immunomedics (Inst); Incyte (Inst); Jacobio (Inst); Lilly (Inst); Lytix Biopharma (Inst); MedImmune (Inst); Medivation (Inst); Merck Sharp and Dohme Corp. (Inst); NIH/NCI (Inst); Novartis (Inst); Pfizer (Inst); Pieris Pharmaceuticals (Inst); Principa Biopharma (Inst); Puma Biotechnology (Inst); RAPT Therapeutics (Inst); Seagen (Inst); Silverback Therapeutics (Inst); Synologic Therapeutics (Inst); Taiho Oncology (Inst); Tesaro (Inst); TransThera Biosciences (Inst)
 
Julia Ann Moore
No Relationships to Disclose
 
Bulent Yilmaz
No Relationships to Disclose
 
Daniel D. Karp
No Relationships to Disclose
 
Ecaterina Elena Dumbrava
Consulting or Advisory Role - Bolt Biotherapeutics
Research Funding - Aileron Therapeutics (Inst); Amgen (Inst); Aprea Therapeutics (Inst); Astex Pharmaceuticals (Inst); Bayer (Inst); Bellicum Pharmaceuticals (Inst); Bolt Biotherapeutics (Inst); Compugen (Inst); Gateway Foundation (Inst); Immunocore (Inst); Immunomedics/Gilead (Inst); Mereo BioPharma 5 (Inst); PMV Pharma (Inst); Rain Therapeutics (Inst); Sanofi (Inst); Seagen (Inst); TRACON Pharma (Inst); Triumvira Immunologics, Inc (Inst); Unum Therapeutics (Inst)
 
Apostolia Maria Tsimberidou
Consulting or Advisory Role - Diaccurate; Vincerx Pharma
Research Funding - Agenus (Inst); IMMATICS (Inst); Karus Therapeutics (Inst); Novocure (Inst); OBI Pharma (Inst); Parker Institute for Cancer Immunotherapy (Inst); Tempus (Inst); Tvardi Therapeutics (Inst)
Travel, Accommodations, Expenses - Japanese Society of Clinical Oncology
 
David S. Hong
Stock and Other Ownership Interests - MolecularMatch; OncoResponse; Telperian
Consulting or Advisory Role - Acuta; Adaptimmune; Alkermes; Alphasights; Amgen; AUM Biosciences; Axiom Biotechnologies; Baxter; Bayer; Boxer Capital; Bridgebio; COG; Cor2Ed; Cowen; EcoR1 Capital; Genentech; Gennao Bio; Gerson Lehrman Group; Gilead Sciences; GroupH; Guidepoint Global; HCW Precision; Immunogen; Infinity Pharmaceuticals; Janssen; Liberum; MedaCorp; Medscape; Numab; Oncologia Brasil; Pfizer; Pharma Intelligence; Precision Oncology Experimental Therapeutics; Prime Oncology; RAIN; ST Cube; Takeda; Tavistock Life Sciences; Trieza Therapeutics; Turning Point Therapeutics; WebMD; YingLing Pharma; ZIOPHARM Oncology
Research Funding - Abbvie (Inst); Adaptimmune (Inst); Adlai Nortye (Inst); Amgen (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol Myers Squibb (Inst); Daiichi Sankyo (Inst); Deciphera (Inst); Eisai (Inst); Endeavor BioMedicines (Inst); Erasca, Inc (Inst); F. Hoffmann LaRoche (Inst); Fate Therapeutics (Inst); Genentech (Inst); Genmab (Inst); Ignyta (Inst); Infinity Pharmaceuticals (Inst); Kite, a Gilead company (Inst); Kyowa (Inst); Lilly (Inst); Loxo (Inst); MedImmune (Inst); Merck (Inst); Mirati Therapeutics (Inst); Mologen (Inst); National Cancer Institute (Inst); Navire (Inst); Novartis (Inst); Numab (Inst); Pfizer (Inst); Pyramid Biosciences (Inst); Seagen (Inst); Takeda (Inst); TCR2 Therapeutics (Inst); Teckro (Inst); Turning Point Therapeutics (Inst); VM Pharma (Inst)
Travel, Accommodations, Expenses - AACR; ASCO; Bayer Schering Pharma; Genmab; Society for Immunotherapy of Cancer; Telperian
 
Jordi Rodon Ahnert
Consulting or Advisory Role - Ellipses Pharma; iOnctura; Kelun Pharmaceuticals/Klus Pharma; Molecular Partners; Peptomyc
Research Funding - AADi (Inst); Amgen (Inst); Bayer (Inst); Bicycle Therapeutics (Inst); BioAtla (Inst); BioMed Valley Discoveries (Inst); Black Diamond Therapeutics (Inst); Blueprint Medicines (Inst); Cellestia Biotech (Inst); Curis (Inst); CytomX Therapeutics (Inst); Deciphera (Inst); Fore Biotherapeutics (Inst); Genmab (Inst); GlaxoSmithKline (Inst); Hummingbird (Inst); Hutchison MediPharma (Inst); IDEAYA Biosciences (Inst); Kelun (Inst); Linnaeus Therapeutics (Inst); Loxo (Inst); Merck Sharp & Dohme (Inst); Merus (Inst); Mirati Therapeutics (Inst); Novartis (Inst); Nuvation Bio (Inst); Pfizer (Inst); Roche (Inst); Spectrum Pharmaceuticals (Inst); Symphogen (Inst); Taiho Pharmaceutical (Inst); Takeda/Millennium (Inst); Tango Therapeutics (Inst); Vall d'Hebron Institute of Oncology/Cancer Core Europe (Inst); Yingli Pharma (Inst)
Travel, Accommodations, Expenses - ESMO
Other Relationship - Boxer Capital; Chinese University of Hong Kong; Tang Advisors; Vall d'Hebron Institute of Oncology/Ministerio De Empleo Y Seguridad Social
 
Daniel J. Booser
No Relationships to Disclose
 
Nuhad K. Ibrahim
Honoraria - Athenex; Immunomedics; Novartis; Roche
Consulting or Advisory Role - Immunomedics
Speakers' Bureau - Novartis; Roche
Travel, Accommodations, Expenses - Novartis; Roche
 
Anthony Paul Conley
Consulting or Advisory Role - Bayer; Deciphera; Deciphera; Genentech; Guidepoint Global; InhibRx; Medscape; Nektar; Novartis; OncLive; Schlesinger Associates
Research Funding - Bavarian Nordic (Inst); Ignyta (Inst); Iovance Biotherapeutics (Inst); MedImmune (Inst); NantHealth (Inst)
Travel, Accommodations, Expenses - Genentech
 
Priya Bhosale
No Relationships to Disclose
 
Cristhiam Mauricio Rojas Hernandez
Research Funding - Aspen Pharma (Inst); Daiichi Sankyo (Inst)
 
Debu Tripathy
Consulting or Advisory Role - AstraZeneca; Genomic Health; GlaxoSmithKline; Novartis; OncoPep; Pfizer
Research Funding - Novartis (Inst); Pfizer (Inst); Polyphor (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Novartis
 
Aung Naing
Consulting or Advisory Role - CSL Behring (I); CytomX Therapeutics; Deka Biosciences; Genome & Company; Horizon Pharma (I); Kymab; Novartis; OncoSec; Pharming NV (I); STCube Pharmaceuticals Inc.; Takeda (I)
Research Funding - Amplimmune; Arcus Biosciences; ARMO BioSciences; Atterocor; Baxalta (I); BioNTech SE; Bristol-Myers Squibb; Calithera Biosciences; Chao Physician-Scientist Awards (I); CytomX Therapeutics; EMD Serono; Healios; Immune Deficiency Foundation (I); ImmuneOncia; Incyte; Jeffrey Modell Foundation (I); Karyopharm Therapeutics; Kymab; Lilly; MedImmune; Merck; Monopteros Therapeutics; NCI; NeoImmuneTech; Neon Therapeutics; Novartis; Pfizer; PsiOxus Therapeutics; Regeneron; Seven and Eight Biopharmaceuticals; Sotio; Surface Oncology; TopAlliance BioSciences Inc
Travel, Accommodations, Expenses - ARMO BioSciences
 
Funda Meric-Bernstam
Employment - MD Anderson Cancer Center
Consulting or Advisory Role - Abbvie; AstraZeneca; Biovica; Black Diamond Therapeutics; Debiopharm Group; eFFECTOR Therapeutics; Eisai; Infinity Pharmaceuticals; Karyopharm Therapeutics; Kolon Life Sciences; Lengo Therapeutics; Loxo; OnCusp Therapeutics; PACT Pharma; Roche; Seagen; Silverback Therapeutics; Tallac Therapeutics; Tyra Biosciences; Xencor; Zentalis; Zymeworks
Research Funding - Abbvie (Inst); Aileron Therapeutics (Inst); AstraZeneca (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Calithera Biosciences (Inst); Curis (Inst); CytomX Therapeutics (Inst); Daiichi Sankyo (Inst); Debiopharm Group (Inst); eFFECTOR Therapeutics (Inst); Genentech (Inst); GlaxoSmithKline (Inst); Guardant Health (Inst); Jounce Therapeutics (Inst); Klus Pharma (Inst); Novartis (Inst); Pfizer (Inst); PUMA Biotechnology (Inst); Seagen (Inst); Taiho Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Zymeworks (Inst)